01 Apr 2011
April 1, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”) announces that it was notified today that on March 31, 2011 the Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in the Company set out below had been awarded under the Executive Annual Incentive Plan (the “Plan”) to the Company’s Executive Directors and Persons Discharging Managerial Responsibility (“PDMRs”). The Shares and ADSs were bought on the market on March 31, 2011 at prices of £18.23 per Share and US$87.5077 per ADS. The awards are in respect of performance in 2010.
|Name of Director||Type of Security||No of Ordinary Shares or ADSs purchased|
|Name of PDMR |
|Tatjana May||Shares ||4,450|
Under the terms of the Plan, the awards will not normally be released to participants for three years. One ADS is equal to three Shares.
In addition, on April 1, 2011 the Company was notified of the release on March 31, 2011 of the Shares and ADSs awarded in 2008 under the Plan. These awards were in respect of performance in 2007. The ADSs below were awarded to Mr Emmens whilst he held the position of Chief Executive Officer of the Company.
In accordance with the rules of the Plan, the following Shares/ADSs were released:
|Name of PDMR||Type of Security||No of Shares/ADSs released||Number of Shares/ADSs sold to satisfy tax reliabilities |
| Angus Russell||Shares||20,068||5,715 |
|Name of PDMR|
|Michael Cola||ADSs||3,528||1,377 |
|Barbara Deptula ||ADSs||3,098||1,020 |
|Sylvie Gregoire||ADSs||790||321 |
|Tatjana May||Shares||11,019||5,635 |
Sufficient Shares or ADSs were sold to satisfy tax liabilities as set out above. Such Shares or ADSs were sold on March 31, 2011, at prices of £18.1818 per Share and $87.1826 per ADS.
This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
|Eric Rojasemail@example.com||+1 781 482 0999|
Notes to editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.